论文部分内容阅读
目的了解鲍曼不动杆菌的临床分布及耐药情况,为合理用药和有效防控院内感染提供依据。方法采用全自动微生物分析仪对2013-2015年送检的临床标本中分离的病原菌进行菌种鉴定和药敏试验,共鉴定出270株鲍曼不动杆菌,并得到相应的药敏试验结果,收集相关数据进行统计分析。结果 270株鲍曼不动杆菌80.11%来自痰液标本,科室分布以职业病科(25.56%)、姑息关怀科(21.85%)、老年科(20.74%)、肿瘤科(15.19%)和重症监护室(13.70%)为主;鲍曼不动杆菌的检出比例为12.57%,耐碳青酶烯类鲍曼不动杆菌占鲍曼不动杆菌的35.56%;对氨苄西林、头孢唑啉、呋喃妥因的耐药率超过了90%,对阿米卡星和复方新诺明的耐药率分别为12.22%和24.81%,其余抗菌药物的耐药率在35%~50%之间,对亚胺培南的耐药率也达到了35.56%。结论鲍曼不动杆菌对常用的13种抗菌药物呈现不同程度的耐药性,应加强鲍曼不动杆菌的耐药性监测,合理选用抗菌药物,预防与控制耐药菌的产生和医院感染暴发的出现。
Objective To understand the clinical distribution and drug resistance of Acinetobacter baumannii in order to provide a basis for rational drug use and effective prevention and control of nosocomial infections. Methods A total of 270 strains of Acinetobacter baumannii were identified by automatic microbiological analyzer for pathogenic bacteria isolated from clinical specimens submitted in 2013-2015. Corresponding results of drug susceptibility test were obtained. Collect relevant data for statistical analysis. Results The results showed that 80.11% of 270 Acinetobacter baumannii were from sputum samples. The departments were divided into occupational diseases (25.56%), palliative care (21.85%), geriatrics (20.74%), oncology (15.19%) and intensive care unit (13.70%). Acinetobacter baumannii was detected in 12.57% of the total, Acinetobacter baumannii accounted for 35.56% of the Acinetobacter baumannii. For ampicillin, cefazolin, nitrofurantoin The resistance rate to amikacin and cotrimoxazole was 12.22% and 24.81%, respectively. The resistance rate of other antibacterials was between 35% and 50% Peinan’s resistance rate also reached 35.56%. Conclusion Acinetobacter baumannii showed resistance to 13 kinds of commonly used antimicrobial agents, should be strengthened Acinetobacter baumannii drug resistance monitoring, rational use of antimicrobial agents, prevention and control of drug-resistant bacteria and nosocomial infections The emergence of the outbreak.